PMID- 17440952
OWN - NLM
STAT- MEDLINE
DCOM- 20070801
LR  - 20171116
IS  - 0270-4137 (Print)
IS  - 0270-4137 (Linking)
VI  - 67
IP  - 9
DP  - 2007 Jun 15
TI  - Immunological evaluation of neoadjuvant peptide vaccination before radical 
      prostatectomy for patients with localized prostate cancer.
PG  - 933-42
AB  - BACKGROUND: The purpose of this study was to determine the safety and immune 
      responses of pre-operative personalized peptide vaccine for patients with 
      localized prostate cancer. METHOD: Ten human leukocyte antigen (HLA)-A24(+) 
      patients with localized prostate cancer received weekly personalized peptide 
      vaccine for six times with positive peptides (up to four kinds of peptides) from 
      16 kinds of vaccine candidates, followed by a retropubic radical prostatectomy 
      (RRP). Eight patients with localized prostate cancer receiving RRP served as the 
      control group. The serum prostate-specific antigen (PSA) level, and 
      peptide-specific cytotoxic T lymphocyte (CTL) precursor analysis by 
      interferon-gamma production, and peptide-reactive immunoglobulin G (IgG) using an 
      enzyme-linked immunosorbent assay were monitored during the treatment. 
      Distributions of CD45RO(+) cells, CD8(+) T cells, and CD20(+) B cells in tissue 
      microarray samples were studied using an immunohistochemical technique. RESULT: 
      The peptide vaccination was safe and well tolerated with no major adverse 
      effects. Increased CTL response and the anti-peptide IgG titer were observed in 
      the post-vaccination samples in 8 of 10 or 8 of 10 patients, respectively. The 
      intensity of CD45RO(+) infiltrating cells in the vaccination group was 
      significantly larger than that in the control group. CD8(+) T cell infiltration 
      was seen only in the vaccinated group. CONCLUSION: Increased immune responses, at 
      both the circulation and tumor sites in the vaccinated group, support the further 
      development of personalized peptide vaccines for patients with localized prostate 
      cancer.
FAU - Noguchi, Masanori
AU  - Noguchi M
AD  - Department of Urology, Kurume University School of Medicine, Kurume, Japan. 
      noguchi@med.kurume-u.ac.jp
FAU - Yao, Akihisa
AU  - Yao A
FAU - Harada, Mamoru
AU  - Harada M
FAU - Nakashima, Osamu
AU  - Nakashima O
FAU - Komohara, Yoshihiro
AU  - Komohara Y
FAU - Yamada, Satoko
AU  - Yamada S
FAU - Itoh, Kyogo
AU  - Itoh K
FAU - Matsuoka, Kei
AU  - Matsuoka K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Prostate
JT  - The Prostate
JID - 8101368
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Vaccines, Subunit)
RN  - EC 3.1.3.48 (Leukocyte Common Antigens)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - *Cancer Vaccines
MH  - HLA-A Antigens/blood
MH  - HLA-A24 Antigen
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - Immunohistochemistry
MH  - Leukocyte Common Antigens/blood
MH  - Lymphocyte Count
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prostate-Specific Antigen/blood
MH  - Prostatectomy
MH  - Prostatic Neoplasms/*immunology/pathology/*surgery
MH  - Vaccines, Subunit/*therapeutic use
EDAT- 2007/04/19 09:00
MHDA- 2007/08/02 09:00
CRDT- 2007/04/19 09:00
PHST- 2007/04/19 09:00 [pubmed]
PHST- 2007/08/02 09:00 [medline]
PHST- 2007/04/19 09:00 [entrez]
AID - 10.1002/pros.20572 [doi]
PST - ppublish
SO  - Prostate. 2007 Jun 15;67(9):933-42. doi: 10.1002/pros.20572.